The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

Clinical Infectious Diseases

Volumn 62, Issue 6, 2015, Pages 784-791

  Girouard, Michael P ^a   Sax, Paul E ^b,c   Parker, Robert A ^a,c   Taiwo, Babafemi ^d   Freedberg, Kenneth A ^a,c,e,f   Gulick, Roy M ^g   Weinstein, Milton C ^f   Paltiel, A David ^h   Walensky, Rochelle P ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h YALE UNIVERSITY   (United States)

Author keywords

ART; Cost effectiveness; Dolutegravir; HIV; Lamivudine

Indexed keywords

ABACAVIR PLUS DOLUTEGRAVIR PLUS LAMIVUDINE; DOLUTEGRAVIR; LAMIVUDINE; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BUDGET; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ECONOMIC ASPECT; FEMALE; HOSPITAL SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAID; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; UNIVARIATE ANALYSIS; VIRUS LOAD; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; STATISTICAL MODEL; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MODELS, STATISTICAL; UNITED STATES;

EID: 84960092410     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ981     Document Type: Article

References (39)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2015. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 10 April 2015.
2. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 1998; 339:1261-8.
3. Riddler SA, Haubrich R, Dirienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-106.
4. Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 2011; 25:2113-22.
5. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22:385-93.
6. Cahn P, Andrade-Villanueva J, Arribas JR, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis 2014; 14:572-80.
7. Perez-Molina JA, Rubio R, Rivero A, et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos( t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis 2015; 15:775-84.
8. Arribas JR, Girard PM, Landman R, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, noninferiority trial. Lancet Infect Dis 2015; 15:785-92.
9. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807-18.
10. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383:2222-31.
11. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013; 381:735-43.
12. Cahn P, The Huesped Foundation. Dolutegravir-lamivudine as dual therapy in naive HIV-infected patients: a pilot study (PADDLE). 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT02211482. Accessed 20 March 2015.
13. Babafemi Taiwo, Northwestern University. Dolutegravir antiretroviral strategy to promote improvement and reduce drug exposure (ASPIRE). 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT02263326. Accessed 20 March 2015.
14. Red Book online. 2015. Available at: http://www.redbook.com/redbook/online/. Accessed 23 March 2015.
15. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-31.
16. Ross EL, Weinstein MC, Schackman BR, et al. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clin Infect Dis 2015; 60:1102-10.
17. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med 2013; 158:84-92.
18. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
19. Cutler DM. Your money or your life: strong medicine for America's health care system. Oxford, UK: Oxford University Press, 2004.
20. Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014; 17:5-14.
21. Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 2010; 50:1512-20.
22. Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One 2012; 7:e31591.
23. Hirsch JD, Gonzales M, Rosenquist A, Miller TA, Gilmer TP, Best BM. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J Manag Care Pharm 2011; 17:213-23.
24. Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014; 384:1942-51.
25. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twicedaily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013; 13:927-35.
26. Fleishman JA, Yehia BR, Moore RD, Korthuis PT, Gebo KA, HIV Research Network. Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr 2012; 60:249-59.
27. Helleberg M, Engsig FN, Kronborg G, et al. Retention in a public healthcare system with free access to treatment: a Danish nationwide HIV cohort study. AIDS 2012; 26:741-8.
28. Levinson DR. Medicaid drug price comparisons: average manufacturer price to published prices. US Department of Health and Human Services, 2005. Available at: http://oig.hhs.gov/oei/reports/oei-05-05-00240.pdf. Accessed 9 April 2015.
29. Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 2014; 58:1297-307.
30. Baio G, Dawid AP. Probabilistic sensitivity analysis in health economics. Stat Methods Med Res 2015; 24:615-34.
31. Centers for Disease Control and Prevention. HIV surveillance report, 2013. Available at: http://www.cdc.gov/hiv/library/reports/surveillance/. Accessed 10 April 2015.
32. Centers for Disease Control and Prevention. Today's HIV/AIDS epidemic. 2015. Available at: http://www.cdc.gov/nchhstp/newsroom/docs/HIVFactSheets/TodaysEpidemic-508.pdf. Accessed 22 April 2015.
33. Nantes University Hospital. Dolutegravir + Rilpivirine Switch Study (DORISS). 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT02069834. Accessed 26 May 2015.
34. ViiV Healthcare. Regimen switch to dolutegravir + rilpivirine from current antiretroviral regimen in human immunodeficiency virus type 1 infected and virologically suppressed adults (SWORD-1). 2015. Available at: https://clinicaltrials. gov/ct2/show/NCT02429791. Accessed 21 May 2015.
35. ViiV Healthcare. Regimen switch to dolutegravir + rilpivirine from current antiretroviral regimen in human immunodeficiency virus type 1 infected and virologically suppressed adults (SWORD-2). 2015. Available at: https://clinicaltrials. gov/ct2/show/NCT02422797. Accessed 26 May 2015.
36. Ethics in Health. The ethics of research studies with no direct benefit to children. 2013. Available at: http://www.ethicsinhealth.org/?p=458. Accessed 21 May 2015.
37. Centers for Medicare and Medicaid. 2015 clinical diagnostic laboratory fee schedule. 2015. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/clinlab.html. Accessed 28 August 2015.
38. Food and Drug Administration. FDA approves new drug to treat HIV infection. 2013. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htm. Accessed 8 September 2015.
39. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994; 14:259-65.